Browse Studies — Arctuva

Phase 1

Phase I Clinical Trial of GPC2 Chimeric Antigen Receptor T (GPC2-CAR T) Cells for Relapsed or Refractory Medulloblastoma in Children and Young Adults

This is a single-site, open-label Phase I treatment study evaluating the manufacturing feasibility and safety of chimeric antigen receptor (CAR) T cells target…

MedulloblastomaCentral Nervous System Embryonal TumorRefractory Medulloblastoma+7 more

Estimated

~$10 – $6,250

Stanford UniversityNCT07087002

Phase 2

Phase 2 Trial of a Novel Peptide Vaccine (PEP-CMV) Targeting CMV Antigen for Newly Diagnosed Pediatric High-grade Glioma and Diffuse Intrinsic Pontine Glioma and Recurrent Medulloblastoma

This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with …

High Grade GliomaDiffuse Intrinsic Pontine GliomaRecurrent Medulloblastoma

Estimated

~$10 – $6,250

Nationwide Children's HospitalNCT05096481

Phase 1

Phase I/II Study of Lutathera in Patients With Recurrent and/or Progressive High-Grade Central Nervous System Tumors and Meningiomas That Demonstrate Uptake on DOTATATE PET

This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS…

High Grade GliomaMeningiomaEmbryonal Tumor+10 more

Estimated

~$10 – $6,250

Nationwide Children's HospitalNCT05278208

Phase 1

A Phase I Dose Escalation Trial of Compartmental Radioimmunotherapy (cRIT) Using 177Lu-DTPA-omburtamab in Pediatric and Adolescent Patients With Recurrent or Refractory B7H3 Expressing Primary or Metastatic CNS Tumors

The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblasto…

Recurrent MedulloblastomaRefractory MedulloblastomaCNS Metastases+1 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07698899